Back to Dashboard

IM048-022 (EXCALIBER-Maint))

一項第 3 期、兩階段、隨機分配、多中心、對照、開放性試驗，在接受自體幹細胞移植 (ASCT) 後的新診斷出多發性骨髓瘤 (NDMM) 參與者中，Iberdomide 維持療法與 Lenalidomide 維持療法之比較

MM•IM048-022 (EXCALIBER-Maint))•IRB: AB-CR-112-038•Last updated: 5/3/2026
Recruiting

Study Design

Study Drug

Iberdomide

Mechanism of Action

CUL4-CRBN E3-Bite

Sponsor

Unknown

Design

III

Control Arm

Lenalidomide

Criteria

Inclusion Criteria

after ASCT with NDMM

Age: Phase: III

Exclusion Criteria

Enrollment

Progress2 / 7

Contact Information

Principal Investigator

陳彩雲

Study Nurse

曾睦捷

Contact Tel

4620

臨床試驗資訊以最新版本計畫書為準 Clinical trial information is subject to the latest version of the Protocol.